Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | TYMP | P19971 | 7/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28827070 | 0.87 | ADORA1 (0.51) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL19127764 | 0.85 | ADORA1 (0.49) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL29832246 | 0.85 | ADORA1 (0.49) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL20637781 | 0.84 | ADORA1 (0.50) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL18042131 | 0.84 | ADORA1 (0.64) | ADORA1TYMPNT5ETRDMT1 | |
| SCHEMBL1068575 | 0.82 | ADORA1 (0.64) | ADORA1TYMPNT5ETRDMT1 | |
| SCHEMBL23630122 | 0.82 | TYMP (0.51) | ADORA1TYMPNT5E | |
| SCHEMBL31075613 | 0.82 | TYMP (0.51) | ADORA1TYMPNT5E | |
| SCHEMBL24191301 | 0.81 | ADORA1 (0.43) | ADORA1TYMPNT5ETRDMT1CARM1 | |
| SCHEMBL8359104 | 0.81 | ADORA1 (0.75) | ADORA1TYMPTRDMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105052-A1 | Oligoribonucleotide derivatives for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105052-A1 | Oligoribonucleotide derivatives for specific inhibition of gene expression | RNGTT, DCLRE1B, POLI | ADORA1 4535/4885TYMP 42/4885NT5E 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.